KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Long-Term Debt Repayments (2019 - 2025)

Historic Long-Term Debt Repayments for BeOne Medicines (ONC) over the last 4 years, with Q3 2025 value amounting to $4.3 million.

  • BeOne Medicines' Long-Term Debt Repayments rose 1971.36% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.5 million, marking a year-over-year increase of 3815.6%. This contributed to the annual value of $28.0 million for FY2024, which is 10475.53% up from last year.
  • As of Q3 2025, BeOne Medicines' Long-Term Debt Repayments stood at $4.3 million, which was up 1971.36% from $12.6 million recorded in Q2 2025.
  • BeOne Medicines' Long-Term Debt Repayments' 5-year high stood at $12.6 million during Q2 2025, with a 5-year trough of -$1.5 million in Q2 2023.
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $4.3 million (2025), whereas its average is $5.7 million.
  • Data for BeOne Medicines' Long-Term Debt Repayments shows a peak YoY increase of 81660.95% (in 2024) and a maximum YoY decrease of 5791.77% (in 2024) over the last 5 years.
  • BeOne Medicines' Long-Term Debt Repayments (Quarter) stood at $5.2 million in 2023, then skyrocketed by 99.89% to $10.4 million in 2024, then plummeted by 59.21% to $4.3 million in 2025.
  • Its Long-Term Debt Repayments stands at $4.3 million for Q3 2025, versus $12.6 million for Q2 2025 and $4.2 million for Q1 2025.